A novel, highly selective IKKα inhibitor (SU1644) used in patient-derived CCS tumour spheroid cultures demonstrated that IKKα inhibition reduced tumour spheroid viability.<h4>Conclusions</h4>These data provide the preclinical rationale for the assessment of topical IKKα inhibitors as a novel preventive treatment for CCS. Here, CHUK is linked to neoplasm.